Taiho Pharmaceutical Co., Ltd.
PharmaTokyo, Japan, Japan · Est. 1936 · 3,000 employees
Taiho Pharmaceutical is a Japanese pharmaceutical company specializing in cancer therapeutics and gastrointestinal drugs with a focus on innovative treatment solutions.
2
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
3
Indications↗
Distinct diseases across all programs
42
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
Pipeline Snapshot
By Phase
2 drugs in development
Phase 31
Phase 11
By Therapeutic Area
top 3
Rare Disease
133%
Hematology
133%
Oncology
133%
R&D Momentum
30/100
Pipeline Velocity
0/100
Trial Completion Rate
92/100
Pipeline Concentration
33/100
Pipeline Freshness
47/100
Strategic Signals
- ↗Active in Rare Disease but thin pipeline — potential licensing opportunity
Activity
Key Events
Jan 17, 2023TrialA Study of TAS3731 in Healthy Adults
Sep 7, 2022TrialA Mass Balance Study of [14C] TAS-303 in Healthy Adult Male Subjects
Jun 28, 2022TrialA Phase 2a Study of TAS5315 in Patients With Chronic Spontaneous Urticaria
Dec 1, 2021TrialA Study of Pimitespib in Combination With Imatinib in Patients With GIST (CHAPTER-GIST-101)
Jun 1, 2021TrialAB122 Platform Study
Mar 22, 2021TrialMass Balance Study of [14C] TAS-205 in Healthy Volunteers
Dec 16, 2020TrialStudy of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities
Nov 1, 2020TrialA Phase 3 Study of TAS-205 in Patients With Duchenne Muscular Dystrophy（REACH-DMD）
4 more events
Oct 30, 2020TrialA Phase 1 Trial of ASTX030 in Patients With Myelodysplastic Syndrome
Sep 4, 2020TrialA Phase 2 Study of TAS-303 in Female Patients With Stress Urinary Incontinence
Aug 30, 2018TrialEfficacy and Safety Study of TAS5315 Compared With Placebo in Participants With Rheumatoid Arthritis.
Sep 9, 2017TrialExploratory Study of TAC-302 in Detrusor Underactivity Patients With Overactive Bladder.
Details
Company Info
Company Overview
$8.5B
Mkt Cap
$2.8B
Revenue
—
Cash
CEOYoshikazu Hirai
Founded1936
Employees3,000
HQTokyo, Japan, Japan
Websitetaiho.co.jp/en/
LinkedInCompany Page
Therapeutic Focus
Oncologygastroenterologyimmunology
Pipeline
Drug Pipeline
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Hematology
Oncology
Rare Disease
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)